NOVARTIS

Pharmaceutical industry inefficiencies stem from high costs per drug approval, frequent C-level executive changes, and strategic R&D restructuring unrelated to science. AI-drug discovery companies should commit to programs until Phase I completion to avoid waste and maximize patient benefit.

FDA approves Kisqali for early-stage breast cancer, reducing recurrence risk by 25%. Phase III trial showed a 25.1% reduction, with a 28.5% risk reduction after four years. Dr. Dennis J. Slamon calls it a 'pivotal moment in improving our approach to care.'

FDA approves Kisqali for early-stage HR-positive, HER2-negative breast cancer, reducing recurrence risk by 25% when taken with aromatase inhibitors for 3 years.

The FDA expanded approval of Kisqali, a CDK4/6 inhibitor, for early-stage HR-positive, HER2-negative breast cancer, reducing recurrence risk by 28.5% after four years when combined with endocrine therapy. This approval broadens access to a broader patient group compared to similar drugs like Verzenio, which is limited to high-risk cases. The cost of Kisqali over three years is approximately $300,000-$400,000, but insurance coverage is expected to increase.

FDA approves Novartis’ Kisqali for early breast cancer at high risk of recurrence, including node-negative disease, potentially adding $3B to annual sales. Kisqali now covers a broader population than competitor Lilly’s Verzenio. Based on NATALEE trial results, Kisqali plus endocrine therapy showed a 25.1% reduction in recurrence risk.

Novartis' Kisqali gains broad FDA approval for early HR+/HER2- breast cancer, reducing recurrence risk by 25% in NATALEE trial, surpassing Eli Lilly's Verzenio in node-negative cases. Kisqali's potential to reach $7 billion in sales is boosted by this approval.

Kyverna appoints Warner Biddle as CEO, Christi Shaw to board. Regenxbio welcomes Mitchell Chan as CFO. Mirador Therapeutics appoints Gregg Gilbert as CFO.

Novartis' Kisqali gets FDA approval for early-stage breast cancer; GSK's vaccines for RSV and shingles co-administered effectively; Novo Nordisk partners with NanoVation for genetic therapies; AstraZeneca's Mene Pangalos joins Omega Funds; Serán Biosciences secures $200M for new facility; Boehringer Ingelheim's nerandomilast shows success in Phase 3 IPF trial.

Power's AI platform simplifies patient access to clinical trials, reducing recruitment delays and enhancing patient understanding, as highlighted at DPHARM Idol Disrupt 2024.

FDA approves Novartis' Kisqali for HR+/HER2- stage II and III early breast cancer, significantly expanding eligible patient population.